Veozah: The First Drug Designed Specifically to Treat Menopausal Hot Flashes
The FDA approved fezolinetant (Veozah), a non-hormonal NK3 receptor antagonist, for moderate to severe hot flashes — the first drug engineered from the ground up for menopausal vasomotor symptoms.
Read the original article at Harvard HealthKairos™'s Take
Kairos™'s perspective on this story
In May 2023, the FDA approved fezolinetant (brand name Veozah) — a once-daily, non-hormonal pill that reduces the frequency and severity of moderate to severe hot flashes caused by menopause. What makes this approval notable is the mechanism: fezolinetant is a neurokinin 3 (NK3) receptor antagonist, a drug class that targets the brain's thermoregulatory circuitry directly. When estrogen levels drop during menopause, a brain chemical called neurokinin B (NKB) becomes overactive in the hypothalamus, narrowing the body's thermoneutral zone and triggering hot flashes. Fezolinetant blocks NKB's receptor, restoring the thermoregulatory balance without replacing hormones.
Clinical trials showed that women taking fezolinetant experienced fewer and less severe hot flashes compared to placebo across a 24-week study period, with effects beginning within the first day of treatment. However, the drug carries important safety considerations: liver function monitoring is required before initiation and periodically through the first nine months of use. In December 2024, the FDA added a warning about rare but serious liver injury, reinforcing the need for clinical oversight. Veozah is not a replacement for hormone therapy in women who also need bone, cardiovascular, or genitourinary support — it is a targeted tool for vasomotor symptoms.
Why This Matters
Veozah's approval matters for two reasons. First, it gives women who cannot or prefer not to take hormones — including breast cancer survivors and women with clotting disorders — a mechanistically distinct option for their most disruptive symptom. Second, it illustrates why granular symptom tracking is clinically valuable. Measuring hot flash frequency, severity, and timing before and after starting treatment is the only way to know whether a therapy is working for a specific individual. A drug that reduces hot flashes by 50 to 60 percent on average will be transformative for some women and insufficient for others. The data that distinguishes between those outcomes lives in the daily tracking log, not in the clinical trial average.
Ready to start tracking?
Kairos™ tracks, scores, and interprets the symptoms of midlife hormonal change — for both women and men.
Get StartedMore from the newsroom
England Adds Menopause to Routine NHS Health Checks for Nearly 5 Million Women
The UK government announced that menopause will be integrated into routine NHS health checks for women aged 40 to 74 — the first time the national health system has systematically screened for menopause symptoms.
Only 8% of Symptomatic Women Receive a Perimenopause or Menopause Diagnosis
A large-scale analysis finds that more than half of women aged 40-64 experience perimenopause or menopause symptoms, yet only 8% receive a confirmed diagnosis — exposing a systemic recognition gap in clinical care.
Sleep Disruption in Menopause: No Approved Therapy Exists for the Most Common Complaint
A review in Menopause reveals that despite affecting 40-56% of peri- and postmenopausal women, sleep disturbance associated with menopause has no specifically approved pharmacological treatment.